$BAX

Deutsche Bank Adjusts Baxter International PT to $27 From $20, Maintains Hold Rating

Deutsche Bank revised its price target for Baxter International to $27 from $20 and kept a Hold rating, according to the bank. Baxter shares were reported around $26.72 in the article’s market snapshot. The change signals an updated valuation view for investors tracking analyst targets and sentiment.

Original reporting
Published Jul 31, 2026, 12:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 1:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$BAX
Neutral
low confidence
Mentioned
$BAX
Relevance
4/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

$BAXNeutralLow
01

Why it matters

For traders, the actionable element is the PT change, but the unchanged rating and lack of new operating or financial data limit decision value.

02

Market read

This is a single-name sell-side PT update with no rating change and no new company-specific fundamentals disclosed in the provided text.

03

What to watch

Without the underlying thesis or updated financial estimates, traders may treat this as routine brokerage maintenance rather than a new fundamental catalyst.

Relevance 4/10Novelty 4/10Timing: pre-market today (07/31/2026)

Background

The text is an analyst note summary from Deutsche Bank adjusting Baxter’s price target while maintaining a Hold rating.

Company-level read

Ticker impact

$BAXNeutralLow confidence
Context

Deutsche Bank raised Baxter International’s price target to $27 from $20 and kept a Hold rating, signaling a valuation view change.

Expected impact

Likely limited near-term impact unless traders view the PT change as a proxy for improving fundamentals.

Evidence & confidence

The article provides only the PT adjustment and rating; it does not include new earnings, guidance, or fundamental drivers.

Market effects

Minor read-through for healthcare/medical devices sentiment, but no sector-wide catalyst is provided.

None indicated beyond a single-name analyst action.

None indicated.

Counterpoint

A higher PT without an upgrade can reflect reduced downside rather than upside, so the market may discount it.

Key entities

  • Baxter International

    Subject of the analyst price-target adjustment and maintained Hold rating.

  • Deutsche Bank

    Brokerage issuing the price target change.

Related articles

$BAXMedAI 8/10

Why Baxter International Stock Skyrocketed by 19% This Week

Baxter International shares rose about 19% over the week after the company reported encouraging Q2 results. Baxter posted $2.96B revenue, up 5% year over year, and GAAP net income of $135M. Adjusted EPS was $0.56. Analysts expected $2.8B revenue and $0.37 adjusted EPS. Baxter raised FY guidance to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.

$MSFTHighAI 8/10

Stocks Rally on Stellar Microsoft Earnings and Chip Stock Strength

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.

$BAXMed

Do Wall Street Analysts Like Baxter International Stock?

Baxter International (BAX) reported Q2 FY2026 results on July 30, with worldwide sales up 5% to $2.96 billion and adjusted EPS of $0.56, helped by a $0.11 per-share IEEPA tariff refund. The company raised FY2026 guidance to 3% to 4% reported sales growth and adjusted EPS of $1.95 to $2.15. Analysts’ consensus remains Hold; TD Cowen raised its price target to $24.

$CORTMed

Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR

The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.

$BAXHighAI 9/10

Why Are Baxter (BAX) Shares Soaring Today

Baxter International (BAX) shares rose about 8.7% after the company reported Q2 results that beat analyst expectations and lifted its full-year outlook. Revenue was $2.96B, up 5.3% YoY, versus $2.79B expected. Adjusted EPS was $0.56 versus $0.37. Baxter raised FY adjusted EPS guidance to $2.05 midpoint.

$BAXHighAI 9/10

Baxter Jumps After Q2 Beat, Boosted 2026 Guidance Reflects Turnaround Progress - Baxter International (NY

Baxter International (BAX) shares rose after the company reported Q2 adjusted earnings of 54 cents, above the 37-cent consensus. Sales rose 5% to $2.96 billion, beating $2.795 billion. Baxter cited inventory and cost reclassification effects partly offset by an IEEPA tariff refund, and raised FY2026 guidance for adjusted EPS to $1.95-$2.15 and sales to $11.581-$11.694B.